PURPOSE Polycythemia vera (PV) is characterized by JAK/STAT activation, thrombotic/
hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV …

RESPONSE is an open-label phase 3 study evaluating the Janus kinase 1/Janus kinase 2
inhibitor ruxolitinib versus best available therapy for efficacy/safety in hydroxyurea-resistant …

Background Polycythaemia vera is a myeloproliferative neoplasm characterised by
excessive proliferation of erythroid, myeloid, and megakaryocytic components in the bone …

BACKGROUND Polycythemia vera (PV) is a myeloproliferative neoplasm associated with
somatic gain‐of‐function mutations of Janus kinase‐2 (JAK2). Therapeutic options are …

RESPONSE-2 is a phase 3 study comparing the efficacy and safety of ruxolitinib with the
best available therapy (BAT) in hydroxyurea-resistant/hydroxyurea-intolerant polycythemia …

The randomized, double‐blind, double‐dummy, phase 3b RELIEF trial evaluated
polycythaemia vera (PV)‐related symptoms in patients who were well controlled with a …

Background Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have a clinical
benefit in patients with polycythemia vera in a phase 2 study. We conducted a phase 3 open …

Background In the pivotal RESPONSE study, ruxolitinib, a Janus kinase (JAK) 1 and JAK2
inhibitor, was superior to best available therapy at controlling haematocrit and improving …

Background The phase 3b, randomised, open-label RESPONSE-2 study in patients with
inadequately controlled polycythaemia vera without splenomegaly showed superiority of the …

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm that is associated with a
substantial symptom burden, thrombohemorrhagic complications, and impaired survival. A …